YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items. A quarter…
Samira Shaikhly, Chief People Officer of Septerna (NASDAQ:SEPN), reported the exercise and immediate sale of 11,798 shares of Common Stock for a transaction value of approximately $355,000, according to an SEC Form 4 filing. Transaction su…
Key Points Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale. No indirect pa…
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim began coverage of SEPN w…
Key Points 15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long’s direct Common Stock holdings, reducing his posit…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company focused on developing small-molecule drugs that target protein misfolding diseases, today announced the appointment of Jae B. Kim, MD,…
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago. These figures are adjusted for non-recurring items.…
Nuvation Bio Inc. (NYSE:NUVB) is one of the 12 Best Stocks to Buy According to Billionaire David Abrams. Nuvation Bio Inc. (NYSE:NUVB) has been featured in the 13F portfolio of Abrams Capital Management since the first quarter of 2021. The…
(RTTNews) - Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering small-molecule therapies targeting G protein-coupled receptors (GPCRs), announced positive results from its Phase 1 clinical trial of SEP-631 for the trea…
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile C…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy from H…
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management…
* Septerna, Inc. press release [https://seekingalpha.com/pr/20300040-septerna-highlights-company-progress-and-reports-third-quarter-2025-financial-results] (SEPN [https://seekingalpha.com/symbol/SEPN]): Q3 GAAP EPS of $0.18. * Revenue of $…
Moderna MRNA shares rallied 13.9% in the last trading session to close at $28.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.5% los…
Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 38% gain over the past fo…
By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit f…
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment…
Jaguar Health, Inc. (NASDAQ:JAGX) is among the best fundamentally strong penny stocks to buy right now. On September 9, 2025, Jaguar Health, Inc. (NASDAQ:JAGX) signed securities purchase agreements with some investors for the issuance and…
[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Se…
Investing.com -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for the second quarter despite beating earnings…
* Septerna, Inc. press release [https://seekingalpha.com/pr/20196588-septerna-highlights-business-progress-and-reports-second-quarter-2025-financial-results] (NASDAQ:SEPN [https://seekingalpha.com/symbol/SEPN]): Q2 GAAP EPS of -$0.56. * Re…
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accele…
Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the announcement, SEPN shares jumped 51%, while NVO…
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license agreement with Danish pharma company, Novo Nordisk NVO, for developing and commercializing oral small molecule medici…
Eli Lilly (NYSE:LLY) shares slid more than 3% on Wednesday after reports emerged that Novo Nordisk (NYSE:NVO) has struck a licensing deal with Septerna (NASDAQ:SEPN) to co-develop obesity, Type 2 diabetes, and metabolic therapies.Eli Lilly…
Madison Mills goes over some of the top stories on this segment of Market Minute. eToro (ETTO.PVT) is skyrocketing after making its debut on the Nasdaq Composite (^IXIC). Exelixis (EXEL) is soaring after the company beat first quarter esti…
The Dow Jones Industrial Average and S&P 500 Index were relatively flat in late-morning trading, whi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Novo Nordisk (NVO) on Wednesday entered into a global collaboration and licensing agreement with Sep PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain competitive. Continue Reading View Comments
Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 weight-loss drug in the form of an oral pill. Septerna's stock is skyrocketing by over 60% in Wednesday's pre-market s…
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to maintain its position as one of two leaders in…